Neuronetics (STIM) Q2 FY26 earnings call

Neuronetics delivered a solid quarter, driven by robust growth in its Greenbrook clinic business and initial positive reception to new Neurostar commercial models. The company demonstrated meaningful progress towards profitability and reduced cash burn, with a focus on operational efficiency and optimizing patient acquisition costs. Management is positioning the company for sustainable growth into 2027 and for future opportunities in interventional psychiatry, including potential psychedelic therapies.